Fonar (FONR) Change In Payables And Accrued Expense : $0.5 Mil (TTM As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Fonar Change In Payables And Accrued Expense?

Fonar's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $0.3 Mil. It means Fonar's Accounts Payable & Accrued Expense increased by $0.3 Mil from Sep. 2023 to Dec. 2023 .

Fonar's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was $0.0 Mil. It means Fonar's Accounts Payable & Accrued Expense increased by $0.0 Mil from Jun. 2022 to Jun. 2023 .

Fonar Change In Payables And Accrued Expense Historical Data

The historical data trend for Fonar's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fonar Change In Payables And Accrued Expense Chart

Fonar Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.43

0.10

-0.10

-0.32

0.02

Fonar Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.09	0.85	-0.15	-0.54	0.30

Fonar Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.5 Mil.

Fonar Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Fonar's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Fonar (FONR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fonar Corp (NAS:FONR) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

STIM NOTV BNR ACRS PRPH VNRX BDSX MDXH BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

FOAA:Germany

Address

110 Marcus Drive, Melville, NY, USA, 11747

Website

https://www.fonar.com

Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue. The company's areas of operations are principally in the United States. It also exports to the United Arab Emirates, England, and Germany.

Executives

Timothy Raymond Damadian	director, officer: CEO, President & Treasurer	110 MARCUS DR., MELVILLE NY 11747
Luciano B Bonanni	officer: Exec VP, COO & PFO	110 MARCUS DR., MELVILLE NY 11747
Raymond V Damadian	director, officer: president	31 FAIRBANKS BLVD, WOODBURY NY 11797
Robert J Janoff	director	32 OSAGE DRIVE, HUNTINGTON STATION NY 11746
Data Charles O	director	347 LINCOLN AVENUE, BEAVER PA 15009
Claudette Chan	director	145 WEST 86TH STREET, APT. 15B, NEW YORK NY 10024
David B Terry	officer: Secretary	BOX 1439, EAST QUOGUE NY 11942
Robert Djerejian	director	303 EAST 57TH STREET, APT 16LA, NEW YORK NY 10022